Jazz Pharma Plc (JAZZ) 145.00 $JAZZ
After Yesterday's Decline of 2.80%, Jazz Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 21, 2:18PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $139.52 to a high of $144.95. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $142.42 on volume of 400,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 145.00 (+2.06)
Watch for Jazz Pharmaceuticals to Potentially Rebound After Falling 1.10% Yesterday
Comtex SmarTrend(R) - Fri Jun 17, 2:51PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $142.42 to a high of $146.74. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $143.66 on volume of 267,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 145.00 (+2.06)
Jazz Pharmaceuticals Offers HAL Study Data on JZP-110
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:42AM CDT
Jazz (JAZZ) presented new data from a Human Abuse Liability (HAL) study on JZP-110 at the annual meeting of the Associated Professional Sleep Societies.
ANIP: 56.27 (+3.48), JAZZ: 145.00 (+2.06), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)
Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability (HAL) Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
PR Newswire Europe - Tue Jun 14, 8:05AM CDT
Jazz Pharmaceuticals plc today announced results from a Human Abuse Liability (HAL) study of JZP-110, an investigational wake-promoting agent in Phase 3 development for the treatment of excessive sleepiness (ES) in adult patients with narcolepsy or with obstructive sleep apnea (OSA). The data will be presented today at the 30th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, taking place June 11-15, 2016 in Denver, Colorado.
JAZZ: 145.00 (+2.06)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX
ACCESSWIRE - Wed Jun 08, 5:36PM CDT
BALA CYNWYD, PA / ACCESSWIRE / June 8, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" or "the Company"
(Nasdaq: CPXX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Jazz Pharmaceuticals plc, ("Jazz".
CPXX: 30.15 (-0.01), JAZZ: 145.00 (+2.06)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.71 (+0.31), JAZZ: 145.00 (+2.06), GRFS: 16.08 (+0.26), PBYI: 33.65 (+2.12)
Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders
PR Newswire - Fri Jun 03, 5:21PM CDT
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Celator Pharmaceuticals, Inc. ("CPXX" or the "Company" in connection with the proposed acquisition of the Company by Jazz Pharmaceuticals plc ("Jazz". On May 31, 2016, the Company announced it had reached a definitive agreement for Jazz to acquire all outstanding shares of CPXX pursuant to a tender offer for $30.25 in cash for each share of Company common stock.
CPXX: 30.15 (-0.01), JAZZ: 145.00 (+2.06)
Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016 Featuring D-Pharm Ltd. & Jazz Pharmaceuticals Plc - Research and Markets
BusinessWire - Fri Jun 03, 10:52AM CDT
Research and Markets has announced the addition of the "Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016" report to their offering.
JAZZ: 145.00 (+2.06)
Jazz Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:19PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
JAZZ: 145.00 (+2.06)
CELATOR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Jazz Pharmaceuticals plc
BusinessWire - Thu Jun 02, 12:22PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" (NASDAQ: CPXX) concerning the sale to Jazz Pharmaceuticals plc. Under the terms of the agreement, Celator shareholders will only receive $30.25 in cash for each share owned.
CPXX: 30.15 (-0.01), JAZZ: 145.00 (+2.06)
Company News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Companies in the News are: WR,GXP,MDT,CPXX,JAZZ,VLKAY
CPXX: 30.15 (-0.01), GXP: 29.56 (-0.04), WR: 55.93 (+0.09), MDT: 85.77 (+1.51), JAZZ: 145.00 (+2.06)
Shareholder Alert: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Celator Pharmaceuticals, Inc. - CPXX
PR Newswire - Tue May 31, 3:29PM CDT
Pomerantz LLP is investigating claims on behalf of investors of Celator Pharmaceuticals Inc. ("Celator" or the "Company" (NASDAQ: CPXX) (ISIN: US15089R1023) (CUSIP: 15089R102) concerning the proposed acquisition of Celator by Jazz Pharmaceuticals plc.
CPXX: 30.15 (-0.01), JAZZ: 145.00 (+2.06)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Celator Pharmaceuticals, Inc. to Jazz Pharmaceuticals plc - CPXX
ACCESSWIRE - Tue May 31, 11:22AM CDT
NEW YORK, NY / ACCESSWIRE / May 31, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
CPXX: 30.15 (-0.01), JAZZ: 145.00 (+2.06)
Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share
PR Newswire Europe - Tue May 31, 2:30AM CDT
Transaction would add VYXEOS(TM), an investigational product in development as a treatment for Acute Myeloid Leukemia (AML), to Jazz Pharmaceuticals' portfolio
CPXX: 30.15 (-0.01), JAZZ: 145.00 (+2.06)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Jazz Pharmaceuticals plc
BusinessWire - Fri May 27, 1:47PM CDT
Levi & Korsinsky announces it has commenced an investigation of Jazz Pharmaceuticals plc ("Jazz Pharmaceuticals" or the "Company" (NASDAQ:JAZZ) concerning possible violations of federal securities laws.
JAZZ: 145.00 (+2.06)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jazz Pharmaceuticals plc - JAZZ
PR Newswire - Fri May 27, 10:41AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Jazz Pharmaceuticals plc ("Jazz" or the Company) (NASDAQ: JAZZ). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
JAZZ: 145.00 (+2.06)
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
PR Newswire Europe - Wed May 18, 3:05PM CDT
Jazz Pharmaceuticals plc today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.
JAZZ: 145.00 (+2.06)
After Yesterday's Decline of 2.80%, Jazz Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 21, 2:18PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $139.52 to a high of $144.95. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $142.42 on volume of 400,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 145.00 (+2.06)
Watch for Jazz Pharmaceuticals to Potentially Rebound After Falling 1.10% Yesterday
Comtex SmarTrend(R) - Fri Jun 17, 2:51PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $142.42 to a high of $146.74. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $143.66 on volume of 267,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 145.00 (+2.06)
Jazz Pharmaceuticals Offers HAL Study Data on JZP-110
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:42AM CDT
Jazz (JAZZ) presented new data from a Human Abuse Liability (HAL) study on JZP-110 at the annual meeting of the Associated Professional Sleep Societies.
ANIP: 56.27 (+3.48), JAZZ: 145.00 (+2.06), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)
Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability (HAL) Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
PR Newswire Europe - Tue Jun 14, 8:05AM CDT
Jazz Pharmaceuticals plc today announced results from a Human Abuse Liability (HAL) study of JZP-110, an investigational wake-promoting agent in Phase 3 development for the treatment of excessive sleepiness (ES) in adult patients with narcolepsy or with obstructive sleep apnea (OSA). The data will be presented today at the 30th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, taking place June 11-15, 2016 in Denver, Colorado.
JAZZ: 145.00 (+2.06)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX
ACCESSWIRE - Wed Jun 08, 5:36PM CDT
BALA CYNWYD, PA / ACCESSWIRE / June 8, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" or "the Company"
(Nasdaq: CPXX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Jazz Pharmaceuticals plc, ("Jazz". CPXX: 30.15 (-0.01), JAZZ: 145.00 (+2.06)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.71 (+0.31), JAZZ: 145.00 (+2.06), GRFS: 16.08 (+0.26), PBYI: 33.65 (+2.12)
Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders
PR Newswire - Fri Jun 03, 5:21PM CDT
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Celator Pharmaceuticals, Inc. ("CPXX" or the "Company"
in connection with the proposed acquisition of the Company by Jazz Pharmaceuticals plc ("Jazz". On May 31, 2016, the Company announced it had reached a definitive agreement for Jazz to acquire all outstanding shares of CPXX pursuant to a tender offer for $30.25 in cash for each share of Company common stock. CPXX: 30.15 (-0.01), JAZZ: 145.00 (+2.06)
Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016 Featuring D-Pharm Ltd. & Jazz Pharmaceuticals Plc - Research and Markets
BusinessWire - Fri Jun 03, 10:52AM CDT
Research and Markets has announced the addition of the "Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016" report to their offering.
JAZZ: 145.00 (+2.06)
Jazz Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:19PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
JAZZ: 145.00 (+2.06)
CELATOR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Jazz Pharmaceuticals plc
BusinessWire - Thu Jun 02, 12:22PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator"
(NASDAQ: CPXX) concerning the sale to Jazz Pharmaceuticals plc. Under the terms of the agreement, Celator shareholders will only receive $30.25 in cash for each share owned. CPXX: 30.15 (-0.01), JAZZ: 145.00 (+2.06)
Company News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Companies in the News are: WR,GXP,MDT,CPXX,JAZZ,VLKAY
CPXX: 30.15 (-0.01), GXP: 29.56 (-0.04), WR: 55.93 (+0.09), MDT: 85.77 (+1.51), JAZZ: 145.00 (+2.06)
Shareholder Alert: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Celator Pharmaceuticals, Inc. - CPXX
PR Newswire - Tue May 31, 3:29PM CDT
Pomerantz LLP is investigating claims on behalf of investors of Celator Pharmaceuticals Inc. ("Celator" or the "Company"
(NASDAQ: CPXX) (ISIN: US15089R1023) (CUSIP: 15089R102) concerning the proposed acquisition of Celator by Jazz Pharmaceuticals plc. CPXX: 30.15 (-0.01), JAZZ: 145.00 (+2.06)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Celator Pharmaceuticals, Inc. to Jazz Pharmaceuticals plc - CPXX
ACCESSWIRE - Tue May 31, 11:22AM CDT
NEW YORK, NY / ACCESSWIRE / May 31, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
CPXX: 30.15 (-0.01), JAZZ: 145.00 (+2.06)
Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share
PR Newswire Europe - Tue May 31, 2:30AM CDT
Transaction would add VYXEOS(TM), an investigational product in development as a treatment for Acute Myeloid Leukemia (AML), to Jazz Pharmaceuticals' portfolio
CPXX: 30.15 (-0.01), JAZZ: 145.00 (+2.06)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Jazz Pharmaceuticals plc
BusinessWire - Fri May 27, 1:47PM CDT
Levi & Korsinsky announces it has commenced an investigation of Jazz Pharmaceuticals plc ("Jazz Pharmaceuticals" or the "Company"
(NASDAQ:JAZZ) concerning possible violations of federal securities laws. JAZZ: 145.00 (+2.06)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jazz Pharmaceuticals plc - JAZZ
PR Newswire - Fri May 27, 10:41AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Jazz Pharmaceuticals plc ("Jazz" or the Company) (NASDAQ: JAZZ). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
JAZZ: 145.00 (+2.06)
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
PR Newswire Europe - Wed May 18, 3:05PM CDT
Jazz Pharmaceuticals plc today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.
JAZZ: 145.00 (+2.06)
